380 related articles for article (PubMed ID: 29550200)
21. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer.
Maines F; Caffo O; Veccia A; Trentin C; Tortora G; Galligioni E; Bria E
Crit Rev Oncol Hematol; 2015 Dec; 96(3):498-506. PubMed ID: 26318091
[TBL] [Abstract][Full Text] [Related]
22. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
[TBL] [Abstract][Full Text] [Related]
23. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
Carles J; Pichler A; Korunkova H; Tomova A; Ghosn M; El Karak F; Makdessi J; Koroleva I; Barnes G; Bury D; Özatilgan A; Hitier S; Katolicka J
BJU Int; 2019 Mar; 123(3):456-464. PubMed ID: 30098093
[TBL] [Abstract][Full Text] [Related]
24. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Corn PG; Agarwal N; Araujo JC; Sonpavde G
Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
[TBL] [Abstract][Full Text] [Related]
25. Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.
Schmidt A; Anton A; Shapiro J; Wong S; Azad A; Kwan E; Spain L; Muthusamy A; Torres J; Parente P; Parnis F; Goh J; Joshua AM; Pook D; Gibbs P; Tran B; Weickhardt A
Asia Pac J Clin Oncol; 2021 Feb; 17(1):36-42. PubMed ID: 32970925
[TBL] [Abstract][Full Text] [Related]
26. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
Thomas C; Brandt MP; Baldauf S; Tsaur I; Frees S; Borgmann H; Jäger W; Bartsch G; Schneider M; Dotzauer R; Neisius A; Haferkamp A
Int Urol Nephrol; 2018 Oct; 50(10):1821-1827. PubMed ID: 30120678
[TBL] [Abstract][Full Text] [Related]
28. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Yanagisawa T; Hata K; Narita S; Hatakeyama S; Mori K; Yata Y; Sano T; Otsuka T; Hara S; Miyajima K; Enei Y; Fukuokaya W; Nakazono M; Matsukawa A; Miki J; Habuchi T; Ohyama C; Shariat SF; Kimura T
Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102
[TBL] [Abstract][Full Text] [Related]
30. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
Wülfing C; Bögemann M; Goebell PJ; Hammerer P; Machtens S; Pfister D; Schwentner C; Steuber T; von Amsberg G; Schostak M
Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
[TBL] [Abstract][Full Text] [Related]
31. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
[TBL] [Abstract][Full Text] [Related]
32. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
[TBL] [Abstract][Full Text] [Related]
33. Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study.
Shimabukuro T; Sakano S; Matsuda K; Kamiryo Y; Yamamoto N; Kaneda Y; Nasu T; Baba Y; Suga A; Yamamoto M; Aoki A; Takai K; Yoshihiro S; Konishi M; Imoto K; Matsuyama H
Int J Clin Oncol; 2013 Feb; 18(1):62-7. PubMed ID: 22068464
[TBL] [Abstract][Full Text] [Related]
34. No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer.
Kosaka T; Hongo H; Watanabe K; Mizuno R; Kikuchi E; Oya M
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1061-1066. PubMed ID: 30283980
[TBL] [Abstract][Full Text] [Related]
35. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
[TBL] [Abstract][Full Text] [Related]
36. Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan.
Yasuoka S; Yuasa T; Ogawa M; Komai Y; Numao N; Yamamoto S; Kondo Y; Yonese J
Anticancer Res; 2019 Oct; 39(10):5803-5809. PubMed ID: 31570485
[TBL] [Abstract][Full Text] [Related]
37. Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands.
Westgeest HM; Kuppen MCP; van den Eertwegh AJM; de Wit R; Coenen JLLM; van den Berg HPP; Mehra N; van Oort IM; Fossion LMCL; Hendriks MP; Bloemendal HJ; van de Luijtgaarden ACM; Ten Bokkel Huinink D; van den Bergh ACMF; van den Bosch J; Polee MB; Weijl N; Bergman AM; Uyl-de Groot CA; Gerritsen WR
Clin Genitourin Cancer; 2019 Oct; 17(5):e946-e956. PubMed ID: 31439536
[TBL] [Abstract][Full Text] [Related]
38. Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices.
Sonpavde G; Bhor M; Hennessy D; Bhowmik D; Shen L; Nicacio L; Rembert D; Yap M; Schnadig I
Clin Genitourin Cancer; 2015 Aug; 13(4):309-318. PubMed ID: 25743206
[TBL] [Abstract][Full Text] [Related]
39. An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective.
Morgans AK; Hutson T; Guan AKD; Garcia D; Zhou A; Drea E; Vogelzang NJ
BMC Health Serv Res; 2022 Jul; 22(1):916. PubMed ID: 35836170
[TBL] [Abstract][Full Text] [Related]
40. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]